Objective: To eveluate the effects of Zhenwu Decoction series combined with conventional Western medicine (CWM) on cardiac function in patients with chronic heart failure (CHF). Methods: A systematic review was performed according to Cochrane Handbook methodology. PubMed, Embase, Cochrane Library, CNKI, WanFang Data, VIP were retrieved from the establishment of the databases to October 26, 2021, and updated until July 31, 2022. Relevant journals were manually searched to collect RCTs about Zhenwu Decoction series combined with CWM for the treatment of patients with CHF. The Cochrane risk-of-bias tool for randomized trials (ROB2) was used to evaluate the risk of bias. The Bayesian Meta analysis method was used to consolidate the data, and a sensitivity analysis was conducted to examine whether the results were reliable. Results: Totally 25 reports were included, involving 2 149 participants. The included studies had an overall high risk of bias. The results of Bayesian random-effects Meta-analysis showed that Zhenwu Decoction series combined with CWM group was superior to CWM group in NYHA classification [cumulative odds ratio (COR) and 95%CrI: 2.50 (1.95, 3.19)], TCM symptom score [COR and 95%CrI: 3.30 (2.20, 5.08)], left ventricular ejection fraction [standardized mean difference (SMD) and 95%CrI:0.86 (0.31, 1.44)], N-terminal pro-B-type natriuretic peptide [SMD and 95%CrI:-1.03 (-2.04, -0.51)], with statistical significance, and the conclusion was reliable by sensitivity analysis. There was no significant difference in B-type natriuretic peptide [SMD and 95%CrI: -0.39 (-0.99, 0.01)] between the two groups. Conclusion: Zhenwu Decoction series combined with CWM can improve cardiac function and clinical status in patients with CHF. Due to the high overall risk of bias included studies, multi-center, large-samples, and high-quality RCTs are more required to verify the conclusion.